FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377563896> ?p ?o ?g. }

• W4377563896 abstract "Objective: To investigate the efficacy and safety of chemotherapy in treating Ph+ ALL based on flumatinib. Methods: The clinical data of 29 patients with Ph+ ALL receiving flumatinib-based chemotherapy in Sichuan Provincial People's Hospital from January 2020 to January 2023 were collected for analysis, with the concentrations of TKI in the peripheral blood, bone marrow, and cerebrospinal fluid of some patients monitored, Cytological experiments on SUP-B15 were conducted in a Ph+ ALL cell line. Results: A total of 29 patients were enrolled, showing the induced CR, 3-month CR, and 6-month CR rates of 96.3%, 87.5%, and 86.7%, respectively after flumatinib-based chemotherapy. The negative conversion ratio of MRD was 82.6%, 91.3%, and 95.6% in 1, 2, and 3 months after treatment, respectively, with 4.3% of patients failing the conversion in 3 months after treatment. The rates of MMR were 73.9%, 87.5%, and 93.3% in 1, 3, and 6 months after treatment, and CMR of 52.2%, 62.5%, and 73.3%, respectively. Among the 29 patients, 11 (37.9%) received transplant and the continuous flumatinib for 1 year after transplantation. The deep remission was maintained in all patients up to the time of follow-up, with the median follow-up of 12 months (1-33 months), progression-free survival (PFS) of 11 months (1-33 months), and median overall survival (OS) of 12 months (1-33 months). The adverse reactions mainly referred to myelosuppression, liver insufficiency and infection that were generally tolerable. In terms of blood concentration, the concentration of flumatinib was ordered as bone marrow > serum > cerebrospinal fluid in Ph+ ALL bone marrow. In contrast, the concentration of dasatinib and imatinib was ordered as serum > bone marrow > cerebrospinal fluid. At the same time, flumatinib has a high probability to cross the blood-brain barrier, while the concentration of cerebrospinal fluid in the patients using Dasatinib was lower compared to the lower limit of detection in this study. Compared with Imatinib and Dasatinib, flumatinib exerted the most potent inhibitory effect on Ph+ ALL cell lines according to pharmacodynamic analysis of SUP-B15 cells. Conclusion: Flumatinib combined with chemotherapy could achieve good efficacy and safety in treating Ph+ ALL, with flumatinib in a high probability of crossing the blood-brain barrier. Flumatinib could be a superior choice to Dasatinib and Imatinib in cell experiments." @default.
• W4377563896 created "2023-05-24" @default.
• W4377563896 creator A5050456659 @default.
• W4377563896 creator A5053180473 @default.
• W4377563896 creator A5057417537 @default.
• W4377563896 creator A5058555863 @default.
• W4377563896 creator A5060056431 @default.
• W4377563896 creator A5060352848 @default.
• W4377563896 creator A5079594267 @default.
• W4377563896 creator A5089011489 @default.
• W4377563896 date "2023-05-05" @default.
• W4377563896 modified "2023-09-24" @default.
• W4377563896 title "Basic and clinical study of efficacy and adverse effects of flumatinib in Ph+ ALL" @default.
• W4377563896 cites W1970263384 @default.
• W4377563896 cites W1993808217 @default.
• W4377563896 cites W1995618464 @default.
• W4377563896 cites W2030796837 @default.
• W4377563896 cites W2269223862 @default.
• W4377563896 cites W2566332174 @default.
• W4377563896 cites W2807190135 @default.
• W4377563896 cites W2887412234 @default.
• W4377563896 cites W2922939125 @default.
• W4377563896 cites W2946505601 @default.
• W4377563896 cites W2964567395 @default.
• W4377563896 cites W2981324571 @default.
• W4377563896 cites W4283329796 @default.
• W4377563896 cites W4310162974 @default.
• W4377563896 cites W4319320894 @default.
• W4377563896 doi "https://doi.org/10.3389/fphar.2023.1178393" @default.
• W4377563896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37214433" @default.
• W4377563896 hasPublicationYear "2023" @default.
• W4377563896 type Work @default.
• W4377563896 citedByCount "0" @default.
• W4377563896 crossrefType "journal-article" @default.
• W4377563896 hasAuthorship W4377563896A5050456659 @default.
• W4377563896 hasAuthorship W4377563896A5053180473 @default.
• W4377563896 hasAuthorship W4377563896A5057417537 @default.
• W4377563896 hasAuthorship W4377563896A5058555863 @default.
• W4377563896 hasAuthorship W4377563896A5060056431 @default.
• W4377563896 hasAuthorship W4377563896A5060352848 @default.
• W4377563896 hasAuthorship W4377563896A5079594267 @default.
• W4377563896 hasAuthorship W4377563896A5089011489 @default.
• W4377563896 hasBestOaLocation W43775638961 @default.
• W4377563896 hasConcept C126322002 @default.
• W4377563896 hasConcept C141071460 @default.
• W4377563896 hasConcept C197934379 @default.
• W4377563896 hasConcept C2776581026 @default.
• W4377563896 hasConcept C2776694085 @default.
• W4377563896 hasConcept C2992053201 @default.
• W4377563896 hasConcept C71924100 @default.
• W4377563896 hasConcept C90924648 @default.
• W4377563896 hasConceptScore W4377563896C126322002 @default.
• W4377563896 hasConceptScore W4377563896C141071460 @default.
• W4377563896 hasConceptScore W4377563896C197934379 @default.
• W4377563896 hasConceptScore W4377563896C2776581026 @default.
• W4377563896 hasConceptScore W4377563896C2776694085 @default.
• W4377563896 hasConceptScore W4377563896C2992053201 @default.
• W4377563896 hasConceptScore W4377563896C71924100 @default.
• W4377563896 hasConceptScore W4377563896C90924648 @default.
• W4377563896 hasLocation W43775638961 @default.
• W4377563896 hasLocation W43775638962 @default.
• W4377563896 hasOpenAccess W4377563896 @default.
• W4377563896 hasPrimaryLocation W43775638961 @default.
• W4377563896 hasRelatedWork W2312528733 @default.
• W4377563896 hasRelatedWork W2355125406 @default.
• W4377563896 hasRelatedWork W2359240367 @default.
• W4377563896 hasRelatedWork W2362301095 @default.
• W4377563896 hasRelatedWork W2363229760 @default.
• W4377563896 hasRelatedWork W2367233677 @default.
• W4377563896 hasRelatedWork W2369852829 @default.
• W4377563896 hasRelatedWork W2375178909 @default.
• W4377563896 hasRelatedWork W2376449511 @default.
• W4377563896 hasRelatedWork W2393133974 @default.
• W4377563896 hasVolume "14" @default.
• W4377563896 isParatext "false" @default.
• W4377563896 isRetracted "false" @default.
• W4377563896 workType "article" @default.